Therapeutic Outlook

Physicians now can treat patients with parkinsonism more effectively and definitively. This improvement of therapeutic outlook has followed a spurt of recent research activity. This research and the drug developments stemning from it are summarized here. 

Future Outlook for Antidepressants. Third-generation antidepressants are expected to combine superior efficacy and improved safety, but are unlikely to reduce the onset of therapeutic action in depressed patients (179). Many dmgs in clinical development as antidepressive agents focus on estabhshed properties such as inhibition of serotonin, dopamine, and/or noradrenaline reuptake, agonistic or antagonistic action at various serotonin receptor subtypes, presynaptic tt2-adrenoceptor antagonism, or specific monoamine—oxidase type A inhibition. Examples include buspirone (3) (only... 

Future Outlook for Pharmacologic Treatment of Abuse and Dependence. The importance of the psychosocial dimension ia predisposiag iadividuals toward substance use disorders and subsequentiy maintaining the disorder caimot be overestimated. Additionally, genetic influences have been found to exert an important influence on HabiUty for dmg abuse. A high comorbidity of psychiatric illnesses with substance use disorders further compHcates therapeutic iaterventions ia such patients (236). 

Although somewhat outside the scope of this text, a non-pharmacological treatment that may become an important therapeutic tool in the future deserves to be mentioned within this outlook section. Initial clinical data indicate that depressive patients are significantly improved after TMS treatment and the procedure is very well tolerated (Berman et til., 2000 McNamara et ul.. 2001). Interestingly for preclinical research, repeated TMS in rats has also been shown to have an antidepressant-like effect (Sachdev et ul., 2002) in the forced swim test described later in this chapter. Whether or not there are psychopharmacological correlates of TMS is unknown at present. 

Research and Markets (2005d), Monoclonal antibody therapeutics current market dynamics future outlook. Available at http //www.researchandmarkets.com/ reportinfo.asp report id=75046 (accessed May 2005). 

Scala SM, Sanderson IC, Moran JR, Cacciatore KC, Perreault JB. Pharmaceutical Therapeutic Catagories Outlook. SG Cowan, New York, Finance report, 2002. 

In the present case, the 1 10 therapeutic index of the racemate - unsatisfactory for a clinical outlook - was risen to the much more acceptable 1 50 ratio for the isolated S(+) antipode. ... 

Figure 1.15 Comparative approval success rates of US biopharmaceutical products and drugs by therapeutic category. (Reproduced with permission from Outlook 2005, Tufts Center for the Study of Drug Development, 2005 4, Tufts Center for the Study of Drug Development.)...

---